$ITOS
iTeos Therapeutics, Inc.

2021 Q3 Form 10-Q Financial Statement

#000156459021056193 Filed on November 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $104.3M $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.761M $4.800M $2.390M
YoY Change 82.52%
% of Gross Profit
Research & Development $16.10M $8.726M $6.137M
YoY Change 84.53% 57.28%
% of Gross Profit
Depreciation & Amortization $176.0K $140.0K $130.0K
YoY Change 25.71%
% of Gross Profit
Operating Expenses $16.10M $13.53M $8.531M
YoY Change 19.05% 42.3%
Operating Profit $79.41M -$13.53M -$8.531M
YoY Change -687.12% 42.3%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$8.484M $265.0K $12.00K
YoY Change -3301.51% -125.53%
Pretax Income $72.41M -$10.69M -$7.252M
YoY Change -777.52% 27.3%
Income Tax $2.771M -$8.000K -$50.00K
% Of Pretax Income 3.83%
Net Earnings $69.64M -$10.68M -$7.202M
YoY Change -752.08% 54.31% 25.14%
Net Earnings / Revenue 66.79%
Basic Earnings Per Share $1.98 -$0.48
Diluted Earnings Per Share $1.86 -$0.48 -$205.5K
COMMON SHARES
Basic Shares Outstanding 35.20M 24.35M
Diluted Shares Outstanding 37.48M 24.35M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $899.8M $340.0M $136.9M
YoY Change 164.64%
Cash & Equivalents $899.9M $340.1M $137.0M
Short-Term Investments
Other Short-Term Assets $8.940M $3.300M $3.200M
YoY Change 170.91%
Inventory
Prepaid Expenses
Receivables $304.0K
Other Receivables
Total Short-Term Assets $914.1M $345.7M $140.4M
YoY Change 164.43%
LONG-TERM ASSETS
Property, Plant & Equipment $2.121M $1.300M $1.300M
YoY Change 63.15%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $410.0K $400.0K $400.0K
YoY Change 2.5%
Total Long-Term Assets $8.242M $5.200M $4.800M
YoY Change 58.5%
TOTAL ASSETS
Total Short-Term Assets $914.1M $345.7M $140.4M
Total Long-Term Assets $8.242M $5.200M $4.800M
Total Assets $922.4M $350.9M $145.2M
YoY Change 162.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.707M $2.400M $2.700M
YoY Change 96.13%
Accrued Expenses $12.19M $6.054M $3.360M
YoY Change 101.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $542.2M $10.30M $7.500M
YoY Change 5164.35%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $181.0K $5.000M $4.600M
YoY Change -96.38%
Total Long-Term Liabilities $181.0K $5.000M $4.600M
YoY Change -96.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $542.2M $10.30M $7.500M
Total Long-Term Liabilities $181.0K $5.000M $4.600M
Total Liabilities $550.3M $15.30M $12.16M
YoY Change 3496.99%
SHAREHOLDERS EQUITY
Retained Earnings -$44.20M -$58.99M
YoY Change -25.08%
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $372.0M $335.6M -$47.92M
YoY Change
Total Liabilities & Shareholders Equity $922.4M $350.9M $145.2M
YoY Change 162.83%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income $69.64M -$10.68M -$7.202M
YoY Change -752.08% 54.31% 25.14%
Depreciation, Depletion And Amortization $176.0K $140.0K $130.0K
YoY Change 25.71%
Cash From Operating Activities $605.0M -$10.23M -$10.00M
YoY Change -6013.99%
INVESTING ACTIVITIES
Capital Expenditures -$532.0K -$100.0K -$110.0K
YoY Change 432.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$532.0K -$100.0K -$100.0K
YoY Change 432.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 441.0K 212.9M -1.110M
YoY Change -99.79%
NET CHANGE
Cash From Operating Activities 605.0M -10.23M -10.00M
Cash From Investing Activities -532.0K -100.0K -100.0K
Cash From Financing Activities 441.0K 212.9M -1.110M
Net Change In Cash 604.9M 202.6M -11.21M
YoY Change 198.65%
FREE CASH FLOW
Cash From Operating Activities $605.0M -$10.23M -$10.00M
Capital Expenditures -$532.0K -$100.0K -$110.0K
Free Cash Flow $605.5M -$10.13M -$9.890M
YoY Change -6077.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0036
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0089
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0090
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0135
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.90
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.94
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.00
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
320117000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
336454000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.92
us-gaap Net Income Loss
NetIncomeLoss
29649000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0066
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0042
us-gaap Net Income Loss
NetIncomeLoss
-23129000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
396443000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2859000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
248000
CY2020Q4 us-gaap Assets
Assets
344558000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3026000
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
7486000
CY2021Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2771000
CY2020Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
4486000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
486000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
542228000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14998000
CY2021Q3 itos Grants Repayable
GrantsRepayable
5548000
CY2020Q4 itos Grants Repayable
GrantsRepayable
5883000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
181000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
480000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2383000
CY2021Q3 us-gaap Liabilities
Liabilities
550340000
CY2020Q4 us-gaap Liabilities
Liabilities
21361000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
36000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Dividends Preferred Stock
DividendsPreferredStock
249000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35257464
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35257464
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35044758
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35044758
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
265000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8185000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
235000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
72413000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10688000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
32420000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23187000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2771000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-8000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2771000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-58000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
69642000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10680000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
617000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73898000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
323197000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
344558000
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
104271000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
104271000
CY2021Q3 us-gaap Revenues
Revenues
104271000
us-gaap Revenues
Revenues
104271000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16102000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8726000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41983000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20688000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8761000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4799000
us-gaap Operating Expenses
OperatingExpenses
72890000
us-gaap Operating Expenses
OperatingExpenses
30299000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
79408000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13525000
us-gaap Operating Income Loss
OperatingIncomeLoss
31381000
us-gaap Operating Income Loss
OperatingIncomeLoss
-30299000
CY2021Q3 itos Grant Income
GrantIncome
1320000
CY2020Q3 itos Grant Income
GrantIncome
2299000
itos Grant Income
GrantIncome
8936000
itos Grant Income
GrantIncome
4969000
itos Fair Value Adjustment For Preferred Stock Tranche Rights Liability
FairValueAdjustmentForPreferredStockTrancheRightsLiability
1265000
CY2021Q3 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
169000
CY2020Q3 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
273000
itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
288000
itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
643000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8484000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
78158000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10287000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
37786000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22808000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-36088000
CY2020Q1 itos Settlement Of Preferred Stock Tranche Right
SettlementOfPreferredStockTrancheRight
4135000
CY2020Q1 itos Temporary Equity Accretion To Redemption Value Increase Decrease
TemporaryEquityAccretionToRedemptionValueIncreaseDecrease
1195000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
186000
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-317000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-5247000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-38526000
CY2020Q2 itos Temporary Equity Accretion To Redemption Value Increase Decrease
TemporaryEquityAccretionToRedemptionValueIncreaseDecrease
2994000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
350000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
205000
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
245000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7202000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-47922000
CY2020Q3 itos Temporary Equity Accretion To Redemption Value Increase Decrease
TemporaryEquityAccretionToRedemptionValueIncreaseDecrease
931000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28498000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.98
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.40
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.86
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.40
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35196995
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24349222
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35134692
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8376860
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37482089
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24349222
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37539184
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8376860
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
69642000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10680000
us-gaap Net Income Loss
NetIncomeLoss
29649000
us-gaap Net Income Loss
NetIncomeLoss
-23129000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8516000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
393000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8137000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
321000
CY2020Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
181903000
CY2020Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
19000000.0
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
210699000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
450000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1714000
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
393000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-10680000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
335626000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-26459000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-243000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
213660000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
289498000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
323197000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2584000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
667000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-305000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13534000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
312609000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3227000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
195000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-74000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3942000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
441000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
8516000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
69642000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
372039000
us-gaap Profit Loss
ProfitLoss
29649000
us-gaap Profit Loss
ProfitLoss
-23129000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
452000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
392000
us-gaap Share Based Compensation
ShareBasedCompensation
9753000
us-gaap Share Based Compensation
ShareBasedCompensation
2250000
itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
10000
itos Fair Value Adjustment For Preferred Stock Tranche Rights And Anti Dilution Warrant Liabilities
FairValueAdjustmentForPreferredStockTrancheRightsAndAntiDilutionWarrantLiabilities
1265000
itos Deferred Rent Adjustments
DeferredRentAdjustments
11000
itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-4927000
itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
3007000
itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
98000
itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
505000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6304000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2346000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1763000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
901000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
4732000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1579000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
2771000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
534155000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-585000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
571956000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19712000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1019000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
222000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
62000
us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
21000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1081000
itos Payments For Initial Public Offering Costs
PaymentsForInitialPublicOfferingCosts
2691000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1303000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
655000
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
2856000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1303000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
339506000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-8728000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
566000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
563450000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
340107000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
181903000
itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
224000
us-gaap Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
5120000
itos Settlement Of Preferred Stock Tranche Right
SettlementOfPreferredStockTrancheRight
4135000
itos Initial Public Offering Costs Included In Accounts Payable
InitialPublicOfferingCostsIncludedInAccountsPayable
270000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19990000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
899904000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3322000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
147000
us-gaap Net Income Loss
NetIncomeLoss
29600000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Use of estimates</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, as well as the related disclosures of contingent assets and liabilities. The Company bases its estimates and assumptions on historical experiences, when available, and on various factors that it believes to be reasonable under the circumstances. The Company evaluates its estimates and assumptions on an ongoing basis. Actual results could differ materially from these estimates.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered the impact of COVID-19 on estimates within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these unaudited condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of the pandemic and is not aware of any specific related event or circumstance that would require it to update its estimates.</p>
CY2021Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
229035000
CY2021Q3 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
229035000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
314636000
CY2020Q4 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
314636000
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2020Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2020Q1 itos Preferred Stock Tranche Rights Liability
PreferredStockTrancheRightsLiability
0
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3942000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7486000
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5025000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4014000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2904000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2662000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2121000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1352000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
500000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
CY2021Q3 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
9038000
CY2020Q4 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
4012000
CY2021Q3 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
3085000
CY2020Q4 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
3208000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
25000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
37000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
41000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
229000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12189000
itos Accounts Receivable Net Current Additions
AccountsReceivableNetCurrentAdditions
304000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
304000
itos Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
625000000
itos Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
104271000
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
520729000
us-gaap Research And Development Arrangement With Federal Government Costs Incurred Net
ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet
1200000
CY2020Q3 itos Proceeds Received From Grants
ProceedsReceivedFromGrants
659000
CY2021Q3 itos Grant Income
GrantIncome
1320000
CY2020Q3 itos Grant Income
GrantIncome
2299000
itos Proceeds Received From Grants
ProceedsReceivedFromGrants
10488000
itos Grant Income
GrantIncome
8936000
itos Grant Income
GrantIncome
4969000
CY2021Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4891000
CY2020Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
133000
CY2021Q3 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
5572000
CY2020Q3 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
5883000
CY2020Q3 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holders to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.60
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
35949000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
25.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.00
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1714000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9753000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2250000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4552396
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.13
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1077150
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
33.37
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
28031
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
27.02
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
212706
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.13
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5388809
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.00
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
78236000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1854930
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0036
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.92
CY2020Q3 itos Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsCommonStock
19.00
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-5466000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-12001000
us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-35671000
us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-15258000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
77879000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2771000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-58000
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.038
us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
68091000
us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-7929000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
72413000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10688000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
32420000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23187000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1313000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2771000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-8000
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.085
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.003
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.038
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.085
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.003
CY2021Q3 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
1577
CY2021Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2020Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
500000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
500000
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0486
CY2021Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3322000
CY2021Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
191000
us-gaap Operating Lease Payments
OperatingLeasePayments
558000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
226000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
579000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
468000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
447000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
402000
CY2021Q3 itos Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1292000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3414000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
545000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2869000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
486000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2383000
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.40
CY2021Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
69642000
CY2020Q3 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-11647000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
29649000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-28498000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35196995
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24349222
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35134692
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8376860
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2285093
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2404492
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37482089
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24349222
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37539184
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8376860
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.98
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.40
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.86

Files In Submission

Name View Source Status
0001564590-21-056193-index-headers.html Edgar Link pending
0001564590-21-056193-index.html Edgar Link pending
0001564590-21-056193.txt Edgar Link pending
0001564590-21-056193-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
itos-10q_20210930.htm Edgar Link pending
itos-10q_20210930_htm.xml Edgar Link completed
itos-20210930.xsd Edgar Link pending
itos-20210930_cal.xml Edgar Link unprocessable
itos-20210930_def.xml Edgar Link unprocessable
itos-20210930_lab.xml Edgar Link unprocessable
itos-20210930_pre.xml Edgar Link unprocessable
itos-ex311_7.htm Edgar Link pending
itos-ex312_8.htm Edgar Link pending
itos-ex321_9.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending